本レポートは最新版が発行されています。 次のリンクをクリックして 最新版をご確認ください。

以前に本レポートを購入済みの方は、ページ右側のダウンロード用リンクより、ダウンロードをお試しください。

3D バイオプリンティング 2017年-2027年:テクノロジー、マーケット、市場予測

化粧品および一般消費者向け商品のテスト、薬剤開発、再生医療における可能性


製品情報 概要 目次 価格 Related Content
この報告書では、3Dバイオプリンティングで利用されているテクノロジーと3Dバイオプリンティングで生成される組織の主な用途について将来の再生医療への応用に焦点を置いて説明しています。また、3Dバイオプリンティングテクノロジーの利点、現在このテクノロジーを推進している要因、最近のトレンド、課題を検討しています。3Dバイオプリンティングは2027年までに18億市場になると推測されています。
Interest in 3D bioprinting has been gaining momentum in recent years, both in the academic and commercial settings. Between 2014 and 2015, the market welcomed numerous 3D bioprinting companies, and new start-ups, spin-outs, and subsidiaries are continuing to emerge. Though investment in the field has been driven on by the futuristic goal of providing solutions for regenerative by way of fabricating organs for transplant, more realistic applications in product development and testing have shown great promise and are already being marketed. Over 2016, several 3D bioprinting companies saw a doubling of revenue, and comparable results are anticipated for the next few years. Given these market trends, IDTechEx forecasts that the global market for 3D bioprinting will reach a value of $1.8 billion by the year 2027.
 
Technology and Applications
 
3D bioprinting can be defined in a variety of ways, and each definition includes and excludes large swathes of key biotechnology markets. In this report, IDTechEx has defined 3D bioprinting as the deposition of living cells in a spatially controlled manner in the absence of any pre-existing scaffold and in more than a single layer. Under this definition, 3D bioprinters are currently based on four main printhead technologies:
 
  • Inkjet
  • Extrusion
  • Laser-induced forward transfer
  • Microvalve
 
This report profiles each technology and its subtypes, and provides key specifications, vendors, and SWOT analyses. This report also introduces and discusses emerging 3D bioprinting technologies of electrospinning, optical bioprinting, label-less magnetic levitation, and acoustic levitation. Technologies and considerations relevant to the 3D bioprinting process, such as software, bioink (including cell selection, growth factors, and scaffold materials), and post-printing maturation are also discussed.
 
Current and future applications for 3D bioprinting discussed in this report include:
 
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalised medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Education
  • Academic research
  • Bionics
 
Regenerative Medicine
 
Special attention is paid to regenerative medicine in this report, as not only does it have the potential to be the largest application for 3D bioprinting in the future, but also one with the highest impact. This report analyses how 3D bioprinting can be applied to regenerative medicine, and focuses on the following tissue types:
 
  • Bone and cartilage
  • Skin
  • Dental
  • Vasculature
  • Complex organs
 
Additionally, discussion of current progress in bringing 3D bioprinted tissues to the clinic is provided, as well future hurdles to be faced. A roadmap of 3D bioprinting in regenerative medicine to the year 2050 is provided.
 
Forecasts
 
This report forecasts the overall 3D bioprinting market to 2027, with in depth discussion of key trends in the short term (2017 - 2021), and those expected in the long term (2022 - 2027). Market forecasts to 2027 are also provided for the 3D bioprinter market segmented by price point, and the 3D bioprinted tissue market segmented by tissue application.
IDTechEx のアナリストへのアクセス
すべてのレポート購入者には、専門のアナリストによる最大30分の電話相談が含まれています。 レポートで得られた重要な知見をお客様のビジネス課題に結びつけるお手伝いをいたします。このサービスは、レポート購入後3ヶ月以内にご利用いただく必要があります。
詳細
この調査レポートに関してのご質問は、下記担当までご連絡ください。

アイディーテックエックス株式会社 (IDTechEx日本法人)
担当: 村越美和子 m.murakoshi@idtechex.com
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Overview
1.2.3D Bioprinting Players
1.3.High Profile Partnerships
1.4.Successful Animal Tests
1.5.3D Bioprinting Market Forecast 2017 - 2027
1.6.3D Bioprinter Market Forecast 2017 - 2027
1.7.3D Bioprinted Tissue Market Forecast 2017 - 2027
1.8.Key Drivers
1.9.Key Challenges
2.INTRODUCTION
2.1.Report Scope / 3D Bioprinting Definition
2.2.3D Bioprinting Process
2.2.1.3D Bioprinting Process: Discussion
2.3.3D Cell Culture Advantages
2.4.3D Bioprinting Advantages
2.5.Key Driver: Regenerative Medicine
2.5.1.Key Driver: Unmet Need in Organs for Transplant
2.6.Key Driver: Product Testing in Medicine
2.6.1.Key Driver: Avoiding Costly Drug Trial Failures
2.7.Key Driver: Product Testing in Consumer Products
2.8.Major Bioprinting Firsts
2.9.3D Bioprinting in 2017
2.10.Key Trends: 3D Bioprinters
2.11.Key Trends: Bioprinted Tissues
2.12.Key Competing Technologies
2.13.Current Technical Challenges
2.14.Current Biological Challenges
2.15.Regulatory Hurdles
2.16.3D Bioprinting SWOT Analysis
3.3D BIOPRINTER TECHNOLOGIES
3.1.From 3D Printing to 3D Bioprinting
3.2.3D Bioprinting Technologies
3.2.1.Comparison of Key Specifications
3.3.3D Bioprinting Technology Comparison
3.4.Inkjet: Introduction
3.4.1.Inkjet: Key Specifications
3.4.2.Inkjet: Thermal
3.4.3.Inkjet: Piezoelectric
3.4.4.Inkjet: Advantages
3.4.5.Inkjet: Challenges
3.4.6.Inkjet: SWOT Analysis
3.5.Extrusion: Introduction
3.5.1.Extrusion: Key Specifications
3.5.2.Extrusion: Pneumatic
3.5.3.Extrusion: Mechanical
3.5.4.Extrusion: Advantages
3.5.5.Extrusion: Challenges
3.5.6.Extrusion: SWOT Analysis
3.6.Laser: Introduction
3.6.1.LIFT: Key Specifications
3.6.2.LIFT: Laser-Induced Forward Transfer
3.6.3.LIFT: Advantages
3.6.4.LIFT: Challenges
3.6.5.LIFT: SWOT Analysis
3.7.Microvalve: Introduction
3.7.1.Microvalve: Key Specifications
3.7.2.Microvalve: Solenoid
3.7.3.Microvalve: Advantages
3.7.4.Microvalve: Challenges
3.7.5.Microvalve: SWOT Analysis
3.8.Emerging Technology
3.8.1.Emerging Technology: Electrospinning
3.8.2.Emerging Technology: Microscale Continuous Optical Bioprinting (µCOB)
3.8.3.Emerging Technology: Paramagnetic and Acoustic
3.9.Industry-wide Technical Challenges
3.10.The Ideal 3D Bioprinter
3.11.Future Technological Directions
4.RELATED TECHNOLOGIES
4.1.Related Technologies
4.2.3D Bioprinting Software
4.3.Bioink Preparation
4.4.Cell Selection
4.4.1.Cell Selection: Regenerative Medicine
4.5.Growth Factors and Other Additives
4.6.Scaffold Materials
4.7.The Ideal Scaffold Material
4.8.Cell Spheroid Printing
4.9.Maturation
5.APPLICATIONS
5.1.Introduction
5.2.Testing of Cosmetics and Other Consumer Goods
5.3.Drug Screening
5.3.1.Drug Screening: Drug Development Process
5.3.2.Drug Screening: Benefits of 3D Bioprinting
5.4.Personalised Medicine
5.5.Regenerative Medicine
5.5.1.Regenerative Medicine: Tissue Roadmap
5.5.2.Regenerative Medicine: Bone and cartilage
5.5.3.Regenerative Medicine: Skin
5.5.4.Regenerative Medicine: Dental
5.5.5.Regenerative Medicine: Vasculature
5.5.6.Regenerative Medicine: Complex Organs
5.6.Cell-Based Biosensors
5.7.Food and Other Animal Products
5.8.Education
5.9.Academic Research
5.10.Bionics
6.MARKETS AND FORECASTS
6.1.Introduction
6.2.Growing 3D Bioprinting Market
6.3.Market Barriers
6.4.Key Losers
6.5.Forecasts
6.6.Overall 3D Bioprinting Market Forecast 2017 - 2027
6.6.1.Overall 3D Bioprinting Market Forecast: Short and Long Term
6.7.3D Bioprinting Value Chain
6.7.1.3D Bioprinting Value Chain: Discussion
6.8.3D Bioprinter Manufacturers
6.8.1.3D Bioprinters by Cost and Technology
6.9.3D Bioprinter Market Forecast 2017 - 2027
6.9.1.3D Bioprinter Market Forecast: Short Term
6.9.2.3D Bioprinter Market Forecast: Long Term
6.10.3D Bioprinting Service Bureaus
6.11.3D Bioprinted Tissue Forecast 2017 - 2027
6.11.1.3D Bioprinted Tissue Forecast: Consumer Products
6.11.2.3D Bioprinted Tissue Forecast: Pharmaceuticals
6.11.3.3D Bioprinted Tissue Forecast: Others
7.REGENERATIVE MEDICINE
7.1.Introduction
7.2.Regulatory Hurdles
7.3.Regenerative Medicine Advanced Therapy Designation
7.4.Ethics
7.5.Scams and Schemes
7.6.From Lab to Clinic
7.7.3D Bioprinting Roadmap to 2050
8.APPENDIX
8.1.List of 3D Bioprinting Companies
8.2.List of Company Profiles
8.2.1.3D Bioprinting Solutions/Vivax Bio
8.2.2.3Dynamic Systems Ltd
8.2.3.Aether Inc.
8.2.4.Aspect Biosystems
8.2.5.Biobots
8.2.6.BioDan Group
8.2.7.Cellenion SASU
8.2.8.Cellink
8.2.9.Digilab Inc.
8.2.10.GeSIM
8.2.11.Microdrop Technologies GmbH
8.2.12.MicroFab
8.2.13.Organovo Holdings, Inc.
8.2.14.PeptiGelDesign Ltd
8.2.15.Poietis
8.2.16.Regemat 3D
8.2.17.SE3D
8.2.18.Sichuan Revotek Co. Ltd.
 

レポート概要

スライド 184
企業数 18
フォーキャスト 2027
 
 
 
 

Subscription Enquiry